Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Veltuzumab

EU orphan designation number: EU/3/09/713   
Active ingredient: Veltuzumab
Indication: Treatment of chronic lymphocytic leukaemia
Sponsor: Immunomedics GmbH
Otto-Röhm-Straße 69, D-64293 Darmstadt, Deutschland

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
02/02/2010 Centralised Orphan - Designation EMEA/OD/100/09 (2010)709 of 29/01/2010